Kinnevik AB/Skr KINV B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kinnevik AB
Kinnevik AB is an investment company based in Stockholm, Sweden, focused on building digital consumer businesses. It operates primarily in the sectors of e-commerce, financial services, healthcare, and telecommunications. Kinnevik was founded in 1936 and has a long history of investing in growth-oriented companies, leveraging strategic partnerships and its deep industry expertise. The company invests with a long-term perspective, aiming to provide capital, operational support, and strategic guidance to its portfolio companies. Kinnevik's geographic focus is predominantly on Europe, and it holds significant stakes in several well-known companies, helping create value through active portfolio management and strategic redeployment of capital.
- Ticker
- Skr KINV B
- Sector
- Finance
- Primary listing
- XSTO
- Employees
- 45
- Headquarters
- Stockholm, Sweden
- Website
- www.kinnevik.com
Kinnevik AB Metrics
BasicAdvanced
kr 20B
-
-kr 27.84
1.37
-
Price and volume
Market cap
kr 20B
Beta
1.37
52-week high
kr 91.26
52-week low
kr 46.78
Average daily volume
1.4M
Financial strength
Current ratio
6.323
Quick ratio
6.217
Long term debt to equity
0.017
Total debt to equity
0.067
Interest coverage (TTM)
-60.85%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
90.22%
Operating margin (TTM)
102.54%
Effective tax rate (TTM)
10.42%
Revenue per employee (TTM)
-kr 189,910,000
Management effectiveness
Return on assets (TTM)
-15.07%
Return on equity (TTM)
-22.88%
Valuation
Price to revenue (TTM)
-2.3
Price to book
0.67
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-94.517
Free cash flow yield (TTM)
-1.06%
Free cash flow per share (TTM)
-0.751
Growth
Revenue change (TTM)
-5,156.80%
Earnings per share change (TTM)
-6,318.49%
3-year revenue growth (CAGR)
6.58%
10-year revenue growth (CAGR)
49.92%
3-year earnings per share growth (CAGR)
2.64%
10-year earnings per share growth (CAGR)
91.88%
What the Analysts think about Kinnevik AB
Analyst ratings (Buy, Hold, Sell) for Kinnevik AB stock.
Analyst projections of the future price of Kinnevik AB stock.
Bulls say / Bears say
The shares ended Q3 at a 42% discount to reported NAV, leaving room for a re-rating if investors regain confidence in the portfolio valuations. (MarketScreener India)
Higher funding-round valuations for Enveda and Tandem Health helped lift NAV in Q3. Kinnevik’s larger portfolio companies also recorded 28% year-to-date sales growth, with EBITDA margins improving by six percentage points. (EFN, MarketScreener India)
Kinnevik has SEK 7.4bn of net cash and is cutting annual management costs towards SEK 200m from 2027. This provides financial flexibility for its shift towards a more focused portfolio of mature, profitable growth businesses. (Kinnevik)
Despite a Q3 recovery, NAV was still down 17% over the first nine months of 2026, mainly because of lower valuation multiples and substantial Climate Tech write-downs. (MarketScreener India)
Private valuations remain fragile: in Q3, Kinnevik cut its Pleo and Oviva valuations by 15% and 13%, respectively, while lower multiples and dilution also weighed on NAV. (MarketScreener India)
The portfolio is still loss-making, with larger companies’ EBITDA margin at negative 4% despite recent improvement. Sustained growth and a successful move towards profitability are needed to support the portfolio’s value. (EFN)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.
Kinnevik AB Financial Performance
Revenues and expenses
Kinnevik AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Kinnevik AB
AllUSDEURGBP
Fund name | Fund size | Skr KINV B weighting |
|---|---|---|
iShares Listed Private Equity$IDPE | $843M | 0.67% |
iShares Listed Private Equity£IPRV | $843M | 0.67% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.10% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.10% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.